Pulmatrix: Pulmatrix Says Formulated Inhaled Migraine Candidate Safe With Fewer GI Side Effects Compared To IV

Pulmatrix Inc (NASDAQ: PULM) completed the Phase 1 trial evaluating the safety and pharmacokinetics of PUR3100 in healthy volunteers. PUR3100 uses the company's iSPERSE formulation technology to create an orally inhaled dry powder dihydroergotamine (DHE) formulation for acute migraine. Twenty-six healthy subjects were enrolled, and each of the four groups contained at ...Full story available on Benzinga.com